Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 EMERYVILLE, Calif., March 26, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Nasdaq: KYTX),…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks